Symbicort® COPD (budesonide/formoterol)
Symbicort® Turbohaler® and Symbicort® pMDI are combinations of an inhaled corticosteroid and a long-acting β2-agonist
Chronic obstructive pulmonary disease (COPD) and Symbicort®
Symbicort® Turbohaler® reduced the incidence of severe exacerbations* by 23% vs formoterol (1.42 vs 1.84 mean exacerbation per patient per year).4
Szafranski study4: this was a 12-month, randomised, double-blind, placebo-controlled, parallel-group study in 812 adult COPD patients (mean age 64 years, mean FEV1 36% predicted normal). Patients received 2 inhalations twice daily of either: Symbicort® Turbohaler® 200/6† (n=208); budesonide 200 µg† (n=198); formoterol 6 µg† (n=201); or placebo (n=205).
Co-primary efficacy variables were:
- Number of severe exacerbations.* Symbicort Turbohaler 200/6 significantly reduced the mean severe exacerbation rate per person per year versus placebo and formoterol and non-significantly versus budesonide.
- FEV1. During the 12-month study period all active treatments significantly increased FEV1 versus placebo. Symbicort 200/6 also increased FEV1 versus budesonide but not versus formoterol.
Symbicort Turbohaler reduced the incidence of severe exacerbations by 24% versus placebo (1.42 vs. 1.87 per patient per year respectively (p=0.035))
Symbicort Turbohaler reduced the incidence of severe exacerbations by 11% versus budesonide (1.42 vs. 1.59 per patient per year respectively (p=0.385)).
*Severe exacerbations were defined as the use of oral steroids and/or antibiotics and/or hospitalisations due to respiratory symptoms.4
†Doses are expressed as metered doses.
COPD = Chronic Obstructive Pulmonary Disease: FEV1 = Forced expiratory volume in 1 second